THE WOODLANDS, Texas,
June 2, 2016 /PRNewswire/
-- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today
announced the launch of www.aboutcarcinoid.com to provide carcinoid
syndrome disease education to patients, caregivers and
physicians. Concurrent with the launching of the website,
Lexicon is also working with seven leading national and regional
patient advocacy groups to conduct the Carcinoid Syndrome Impact
Survey, which is designed to improve understanding of the impact
that carcinoid syndrome has on patient lives. Additional
information on the survey can be found at
www.aboutcarcinoid.com.
Aboutcarcinoid.com was created with input from a diverse group
of carcinoid syndrome patients, their loved ones and the physicians
who treat them. The website is designed to raise awareness of
carcinoid syndrome and provide practical information and tools for
patients and physicians. Aboutcarcinoid.com is intended for
educational purposes only and is not intended to provide medical
advice. Every person's medical situation is unique and any
questions should be directed to a healthcare professional.
"Carcinoid tumors are generally slow-growing. Therefore,
while tumor control is particularly important, maintaining social,
emotional, and physical functionality is paramount in treating
patients with carcinoid syndrome," said Jonathan Strosberg, M.D., Lead of the
Neuroendocrine Tumor Division and Associate Professor at H. Lee
Moffitt Cancer Center. "Many patients dramatically alter their
daily lives to accommodate the effects of carcinoid syndrome and
patients may experience urgent and debilitating diarrhea or even
lose complete control of bowel function."
The Carcinoid Syndrome Impact Survey is unique in that it brings
together the collective efforts of seven leading national and
regional patient advocacy groups:
- Carcinoid Cancer Foundation (CCF)
- Neuroendocrine Cancer Awareness Network (NCAN)
- Neuroendocrine Tumor Research Foundation (NETRF)
- Healing Net Foundation
- Los Angeles Carcinoid Neuroendocrine Tumor Society
(LACNETS)
- NorCal CarciNET Community
- Big Apple NETs
"By working together, it is our shared hope to shine a much
needed spotlight on the detrimental effects that carcinoid syndrome
has on patient lives, while raising awareness and understanding of
this syndrome in the physician communities," said Grace Goldstein, Chief Operating Officer of
Carcinoid Cancer Foundation, a national patient advocacy and
information organization.
About Carcinoid Syndrome
Carcinoid syndrome is a rare disease affecting thousands of
cancer patients with metastatic neuroendocrine tumors that have
spread to the liver and other organs from the gastrointestinal
tract. Overproduction of serotonin within these metastatic
neuroendocrine tumor cells is a driver of carcinoid syndrome, which
is characterized by debilitating diarrhea, facial flushing,
abdominal pain, heart valve damage and other serious
consequences. The severe and unpredictable diarrhea
associated with carcinoid syndrome has a profound impact on cancer
patients' lives, often preventing them from participating in daily
activities.
About Lexicon
Lexicon is a fully integrated biopharmaceutical company that is
applying a unique approach to gene science based on Nobel
Prize-winning technology to discover and develop precise medicines
for patients with serious, chronic conditions. Through its
Genome5000™ program, Lexicon scientists have studied the role and
function of nearly 5,000 genes over the last 20 years and have
identified more than 100 protein targets with significant
therapeutic potential in a range of diseases. Through the precise
targeting of these proteins, Lexicon is pioneering the discovery
and development of innovative medicines to safely and effectively
treat disease. Lexicon has a pipeline of promising drug candidates
in clinical and pre-clinical development in oncology, diabetes and
metabolism. For additional information please visit
www.lexpharma.com.
Safe Harbor Statement
This press release contains "forward-looking statements,"
including statements relating to Lexicon's growth and future
operating results, discovery and development of products, strategic
alliances and intellectual property, as well as other matters that
are not historical facts or information. All forward-looking
statements are based on management's current assumptions and
expectations and involve risks, uncertainties and other important
factors, specifically including the risk that clinical studies of
its drug programs may be halted, delayed or otherwise not
demonstrate safety or efficacy, the risk that the FDA and other
regulatory authorities may not grant regulatory approval of its
drug programs in accordance with Lexicon's currently anticipated
timelines or at all, and the risk that such regulatory approvals,
if granted, may have significant limitations on the approved use of
its drug candidates. As a result, Lexicon's drug candidates may
never be successfully commercialized. Other risks include Lexicon's
ability to meet its capital requirements, successfully conduct
preclinical and clinical development and obtain necessary
regulatory approvals of its drug candidates, achieve its
operational objectives, obtain patent protection for its
discoveries and establish strategic alliances, as well as
additional factors relating to manufacturing, intellectual property
rights, and the therapeutic or commercial value of its drug
candidates. Any of these risks, uncertainties and other factors may
cause Lexicon's actual results to be materially different from any
future results expressed or implied by such forward-looking
statements. Information identifying such important factors is
contained under "Risk Factors" in Lexicon's annual report on Form
10-K for the year ended December 31,
2015, as filed with the Securities and Exchange Commission.
Lexicon undertakes no obligation to update or revise any such
forward-looking statements, whether as a result of new information,
future events or otherwise.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/lexicon-announces-the-launch-of-aboutcarcinoidcom-to-provide-carcinoid-syndrome-disease-education-to-patients-caregivers-and-physicians-300279049.html
SOURCE Lexicon Pharmaceuticals, Inc.